GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
Published: Jan 07, 2009
LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. . The tender offer expired at 12:00 midnight, New York City time, on Tuesday, January 6, 2009.
The depositary for the tender offer has advised GSK that shareholders of Genelabs have tendered and not withdrawn a total of approximately 39,250,243 shares of Genelabs common stock. These shares, together with the shares beneficially owned by GSK and its wholly-owned subsidiaries, represent approximately 88.55 percent of the outstanding shares of Genelabs on a fully diluted basis. Gemstone has accepted for payment all Genelabs shares tendered in the offer.
GSK also announced that Gemstone exercised its "top-up" option in accordance with the previously announced merger agreement with Genelabs. The exercise of the top-up option allowed Gemstone to increase its share ownership percentage of Genelabs through the purchase of newly-issued shares of Genelabs common stock at the tender offer price. As a result, Gemstone owns more than 90 percent of the outstanding shares of Genelabs common stock and intends to effect a short-form merger as promptly as practicable, without the need for a meeting of Genelabs shareholders. In the merger, Gemstone will acquire all other Genelabs shares (other than those as to which holders properly exercise dissenters' rights) at the same $1.30 per share price, without interest and less any required withholding taxes, that was paid in the tender offer. As a result of the merger, Genelabs will become a wholly-owned subsidiary of GSK and Genelabs shares will cease to be traded on The NASDAQ Capital Market.
About GlaxoSmithKline plc
GlaxoSmithKline plc -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at www.gsk.com.
CONTACT: UK Media: Philip Thomson, Alice Hunt or Stephen Rea, all at (020)
8047 5502; or US Media: Nancy Pekarek or Mary Anne Rhyne, both at
+1-919-483-2839, or Sarah Alspach or Melinda Stubbee, both at
+1-215-751-7709; or for European Analyst and Investors: David Mawdsley,
(020) 8047-5564, or Sally Ferguson, (020)-8047-5543, or Gary Davies,
(020)-8047- 5503; or for US Analyst and Investors: Tom Curry,
+1-215-751-5419, or Jen Hill, +1-215-751-7002, all of GlaxoSmithKline plc
Web site: http://www.gsk.com/